Recurrent episodes of hypoglycemia induced by moxifloxacin

Singal, Dinesh; Mittal, Amit; Prakash, Anukalp

doi:10.4103/0253-7613.111908

Cited by 5 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed a classical surge in the serum insulin levels with a subsequent decrease in the blood glucose levels. Though there are reports of dysglycemia regarding the use of fluoroquinolones in treating different ailments with quinolones, previous case studies reported that quinolones induce dysglycemia [ 17 , 18 , 19 , 20 ]. However, there are also reports of hyperglycemia with Moxifloxacin , Gatifloxacin , and levofloxacin .…”

Section: Discussionmentioning

confidence: 99%

Insulinotropic Potential of Moxifloxacin and Gemifloxacin: An In Vivo Rabbits Model Study Followed by Randomized Phase I Clinical Trial

et al. 2022

View full text Add to dashboard Cite

Fluoroquinolones (FQs) have been reported to cause dysglycemia in both diabetic and non-diabetic patients. However, diabetic patients are usually on polypharmacy, so we cannot attribute the dysglycemia specifically to FQs. To answer the question as to whether Moxifloxacin and Gemifloxacin influence blood glucose levels and serum insulin levels or otherwise, rabbits were used as experimental animals in an in vivo model followed by a phase I randomized clinical trial in euglycemic healthy volunteers. The effects on the serum insulin and blood glucose levels in the Moxifloxacin and Gemifloxacin treated groups were, respectively, determined on the fifth day in both the in-vivo rabbits model and in the test subjects of the phase I clinical trial. The effects of these drugs were also checked on the histomorphology of the pancreas in the rabbits. The findings of our study suggest that Moxifloxacin and Gemifloxacin significantly (p < 0.05) reduced the blood glucose levels via a subsequent significant shift in the serum insulin levels both in the in vivo animal model and in the test subjects of the phase I clinical trial. No prominent effects on the beta cells histomorphology were noted in this study. Moxifloxacin showed a more significant effect than Gemifloxacin. The insulinotropic effect was comparable to the effect of Glibenclamide. It is concluded that Moxifloxacin and Gemifloxacin have a significant blood glucose lowering effect mediated through insulinotropic action. (Clinical Trials.gov identifier: NCT04692623).

show abstract

Section: Discussionmentioning

confidence: 99%

Insulinotropic Potential of Moxifloxacin and Gemifloxacin: An In Vivo Rabbits Model Study Followed by Randomized Phase I Clinical Trial

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Fluoroquinolones, on the other hand, augments the pharmacodynamics action of sulfonylurea through inhibiting adenosine triphosphate-potassium channels (ATP-K+) in pancreatic B-cells, thereby leading to earlier depolarization, increasing insulin release causing hypoglycemia [9].…”

Section: Discussionmentioning

confidence: 99%

Clarithromycin and Glipizide Drug-drug Interaction Leading to Refractory Hypoglycemia

Ruan¹,

Tan²,

Tan³

2019

Cureus

View full text Add to dashboard Cite

show abstract

“…Several case reports have indicated that quinolone users face significant risk of severe hypoglycemia ( 3 , 6 - 8 ). A recent cohort study from Taiwan showed that moxifloxacin, levofloxacin, and ciprofloxacin were associated with a higher risk of hypoglycemia and hyperglycemia than macrolides and cephalosporins ( 9 ).…”

Section: Discussionmentioning

confidence: 99%

Severe and Recurrent Hypoglycemia Caused by Garenoxacin in a Patient not Taking Hypoglycemic Drugs

et al. 2018

View full text Add to dashboard Cite

Quinolones are known to induce hypoglycemia, although there is no written report of garenoxacin-induced hypoglycemia. We herein report a case of garenoxacin-induced hypoglycemia in a patient not taking hypoglycemic drugs. An 89-year-old Japanese woman with type 2 diabetes and chronic renal insufficiency requiring hemodialysis was admitted to the emergency department in a comatose state. Her serum glucose measured 1 mg/dL on arrival. The patient had not taken any hypoglycemic drugs recently and had never experienced a hypoglycemic episode. She had received a four-day course of garenoxacin treatment before the emergency admission. Clinicians should therefore recognize the potential risk of hypoglycemia during garenoxacin therapy.

show abstract

Recurrent episodes of hypoglycemia induced by moxifloxacin

Abstract: An elderly diabetic male with pneumonia presented with multiorgan failure. He developed hypoglycemic episodes with moxifloxacin that responded only to withdrawal of moxifloxacin.

Cited by 5 publications

References 6 publications

Insulinotropic Potential of Moxifloxacin and Gemifloxacin: An In Vivo Rabbits Model Study Followed by Randomized Phase I Clinical Trial

Insulinotropic Potential of Moxifloxacin and Gemifloxacin: An In Vivo Rabbits Model Study Followed by Randomized Phase I Clinical Trial

Clarithromycin and Glipizide Drug-drug Interaction Leading to Refractory Hypoglycemia

Severe and Recurrent Hypoglycemia Caused by Garenoxacin in a Patient not Taking Hypoglycemic Drugs

Contact Info

Product

Resources

About